Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic options
Satisfy requirements for prior treatments per tumor type as outlined in the protocol
Measurable disease per RECIST v1.1
Participant willing to provide tumor biopsies
Adequate organ function
Agree to contraception requirements as outlined in the protocol
Life expectancy greater than 12 weeks
You may not be if
Any clinically significant cardiac disease
Any clinically significant corneal disorder
Known, active, and uncontrolled hepatitis B virus (HBV), hepatitis virus (HCV) or human immunodeficiency virus (HIV), or uncontrolled chronic or ongoing infectious requiring intravenous treatment.
Active significant neurologic disorders
Requires home oxygen
Active autoimmune disease
History or active skin disease requiring frequent treatment
History of major immunologic reaction to prior immunoglobulin G-containing agent
Clinically significant ascites or liver disease
Uncontrolled diabetes or diabetic neuropathy
Active bleeding disorders
Participation in a concurrent clinical study in the treatment period
Pregnant or lactating or planning to become pregnant
Known hypersensitivity to IDP-001 or any of its ingredients
Unresolved toxicities from previous anticancer therapy
Has had a seizure prior to Screening
Prior solid organ transplant or allogeneic stem cell transplant
Current endocrinopathy
History of Stevens-Johnson syndrome or Toxic Epidermal Necrolysis
History or interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids
Stroke or transient ischemic attack prior to Screening
Participant has any other condition or illness that, in the opinion of the Investigator, may compromise participant safety, compliance, or interfere with the conduct and evaluation of the current study.
Clareo Health | A Study of IDP-001 in Advanced or Metastatic Solid Tumors
